284 related articles for article (PubMed ID: 22200658)
1. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.
David M; Ribeiro J; Descotes F; Serre CM; Barbier M; Murone M; Clézardin P; Peyruchaud O
Int J Oncol; 2012 Apr; 40(4):1133-41. PubMed ID: 22200658
[TBL] [Abstract][Full Text] [Related]
2. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.
Marshall JC; Collins JW; Nakayama J; Horak CE; Liewehr DJ; Steinberg SM; Albaugh M; Vidal-Vanaclocha F; Palmieri D; Barbier M; Murone M; Steeg PS
J Natl Cancer Inst; 2012 Sep; 104(17):1306-19. PubMed ID: 22911670
[TBL] [Abstract][Full Text] [Related]
3. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.
Chen M; Towers LN; O'Connor KL
Am J Physiol Cell Physiol; 2007 May; 292(5):C1927-33. PubMed ID: 17496233
[TBL] [Abstract][Full Text] [Related]
4. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
[TBL] [Abstract][Full Text] [Related]
5. The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer.
Sahay D; Leblanc R; Grunewald TG; Ambatipudi S; Ribeiro J; Clézardin P; Peyruchaud O
Oncotarget; 2015 Aug; 6(24):20604-20. PubMed ID: 26098771
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.
Yu S; Murph MM; Lu Y; Liu S; Hall HS; Liu J; Stephens C; Fang X; Mills GB
J Natl Cancer Inst; 2008 Nov; 100(22):1630-42. PubMed ID: 19001604
[TBL] [Abstract][Full Text] [Related]
8. A549 cells as a model to study endogenous LPA
Carmona-Rosas G; Alfonzo-Méndez MA; Hernández-Espinosa DA; Romero-Ávila MT; García-Sáinz JA
Eur J Pharmacol; 2017 Nov; 815():258-265. PubMed ID: 28943105
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid signaling via LPA
Fukushima K; Takahashi K; Yamasaki E; Onishi Y; Fukushima N; Honoki K; Tsujiuchi T
Exp Cell Res; 2017 Mar; 352(1):139-145. PubMed ID: 28189636
[TBL] [Abstract][Full Text] [Related]
11. LPA
Wang F; Liu S; Pei J; Cai L; Liu N; Liang T; Dong X; Cong X; Chun J; Chen J; Hu S; Chen X
Theranostics; 2020; 10(24):10892-10907. PubMed ID: 33042260
[No Abstract] [Full Text] [Related]
12. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment.
Venkatraman G; Benesch MG; Tang X; Dewald J; McMullen TP; Brindley DN
FASEB J; 2015 Mar; 29(3):772-85. PubMed ID: 25398768
[TBL] [Abstract][Full Text] [Related]
13. Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.
Lee SC; Fujiwara Y; Liu J; Yue J; Shimizu Y; Norman DD; Wang Y; Tsukahara R; Szabo E; Patil R; Banerjee S; Miller DD; Balazs L; Ghosh MC; Waters CM; Oravecz T; Tigyi GJ
Mol Cancer Res; 2015 Jan; 13(1):174-85. PubMed ID: 25158955
[TBL] [Abstract][Full Text] [Related]
14. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
Zhao PF; Wu S; Li Y; Bao G; Pei JY; Wang YW; Ma Q; Sun HJ; Damirin A
Eur J Pharmacol; 2020 Feb; 868():172886. PubMed ID: 31866407
[TBL] [Abstract][Full Text] [Related]
15. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
[TBL] [Abstract][Full Text] [Related]
16. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature.
Schleicher SM; Thotala DK; Linkous AG; Hu R; Leahy KM; Yazlovitskaya EM; Hallahan DE
PLoS One; 2011; 6(7):e22182. PubMed ID: 21799791
[TBL] [Abstract][Full Text] [Related]
17. An Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular Senescence of Mesenchymal Stromal Cells and Promotes Growth and Vascularization of Multiple Myeloma.
Kanehira M; Fujiwara T; Nakajima S; Okitsu Y; Onishi Y; Fukuhara N; Ichinohasama R; Okada Y; Harigae H
Stem Cells; 2017 Mar; 35(3):739-753. PubMed ID: 27641212
[TBL] [Abstract][Full Text] [Related]
18. Differential targeting of lysophosphatidic acid LPA
Olianas MC; Dedoni S; Onali P
Eur J Pharmacol; 2023 Nov; 959():176064. PubMed ID: 37758013
[TBL] [Abstract][Full Text] [Related]
19. LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer.
Zhao P; Yun Q; Li A; Li R; Yan Y; Wang Y; Sun H; Damirin A
Med Oncol; 2022 Jan; 39(2):17. PubMed ID: 34982278
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-3, in human pancreatic cancer.
Liao Y; Mu G; Zhang L; Zhou W; Zhang J; Yu H
Dig Dis Sci; 2013 Dec; 58(12):3524-33. PubMed ID: 24061591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
